Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Contract revenue		$ 756
Operating expenses
Research and development	7,591	3,347
General and administrative	6,189	2,607
Total operating expenses	13,780	5,954
Loss from operations	(13,780)	(5,198)
Other income (expense), net
Interest income	15	47
Interest expense and other, net		(188)
Change in estimated fair value of preferred unit warrant		(216)
Loss before income taxes	(13,765)	(5,555)
Income tax expense	(63)	(43)
Net loss and comprehensive loss	(13,828)	(5,598)
Net loss attributable to non-controlling interest	(7,605)	$ (5,598)
Net loss attributable to Rani Therapeutics Holdings, Inc.	$ (6,223)
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc., basic and diluted	$ (0.29)
Weighted-average Class A common shares outstanding-basic and diluted	21,409